Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients

Gut

Volumn 39, Issue 2, 1996, Pages 279-283

  Ruszniewski, P ^a   Ducreux, M ^b   Chayvialle, J A ^c   Blumberg, J ^d   Cloarec, D ^e   Michel, H ^f   Raymond, J M ^g   Dupas, J L ^h   Gouerou, H ⁱ   Jian, R ^j   Genestin, E ^d   Bernades, P ^a   Rougier, P ^h  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d IPSEN   (France)

^e CHU de Nantes   (France)

^f HÔPITAL SAINT ELOI   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h Department of Gastroenterology ^*

ⁱ CHU MORVAN   (France)

^j SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Carcinoid syndrome; Carcinoid tumours; Somatostatin analogue; Tumour growth

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLIC; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; SYMPTOMATOLOGY;

EID: 9444295904     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.2.279     Document Type: Article

References (26)

1. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 2: 225-9.
2. Godwin JD. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 2: 560-9.
3. Moertel CG. An odessey in the land of small tumors. J Clin Oncol 1987; 10: 1503-23.
4. Kowlessar OD. The carcinoid syndrome. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease. Pathophysiology, diagnosis, management. 4th ed. Philadelphia: W B Saunders, 1989: 1560-70.
5. Kvols LK. Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am 1989; 2: 557-68.
6. Sjoerdsma A, Lovenberg W, Engelman K. Serotinin now; clinical implications of inhibiting its synthesis with parachlorophenylalanine. Ann Intern Med 1970; 73: 607-29.
7. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991; 67: 33-6.
8. Frölich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D. The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055-7.
9. Long RG, Peters JR, Bloom SR, Brown MR, Vale W, Rivier JE, et al. Somatostatin, gastrointestinal peptides and the carcinoid syndrome. Gut 1981; 22: 549-53.
10. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
11. Gorden P, Comi RJ, Maton PN, Go VLW. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35-50.
12. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 11: 663-6.
13. Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg 1993; 17: 504-10.
14. Souquet JC, Sassolas G, Forichon J, Champetier P, Partensky C, Chayvialle JA. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987; 59: 1654-60.
15. Trautmann ME, Neuhaus C, Lenze H, Benning R, Benning M, Dennler HJ, et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Horm Metab Res 1995; 27: 24-7.
16. Sassolas G, Khalfallah Y, Chayvialle JA. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin and digestive peptides in normal men. J Clin Endocrinol Metab 1989; 68: 239-46.
17. Morange I, De Boisvilliers F, Chanson P, Lucas B, Dewailly D, Catus F, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79: 145-51.
18. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34 (suppl): 14-27S.
19. Kraenzlin ME, Ch'ng JLC, Wood SM, Carr KH, Bloom SR. Long term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185-7.
20. Scherübl H, Wiedenmann B, Riecken EO, Thomas F, Böhme E, Räth U. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 1994; 10: 1591-2.
21. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244-8.
22. Scarpignato C. Somatostatin analogues in the management of endocrine tumors of the pancreas. In: Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas. Front Gastrointest Res. Basel: Karger, 1995; 23: 385-414.
23. Chayvialle JA. Sandostatin and carcinoid tumours in France: experience in the Lyon area. Digestion 1990; 45 (suppl 1): 23-6.
24. Dowling RH, Hussaini SH, Murphy GM, Wass JAH. Gallstones during octreotide therapy. Digestion 1993; 54 (suppl 1): 107-20.
25. Ruszniewski P, Ducreux M, Michel H, Amouretti M, Gouerou H, Wemeau JL, et al. Long-term treatment of the carcinoid syndrome by lanreotide: results of a prospective multicentre study. Gastroenterology 1994; 106 (suppl): A319.
26. Lamberts SWJ, Van Der Ley AJ, De Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.